insights_auto
Why is NTLA down 8.06%?
Dive Deeperchevron_right
NTLA:NASDAQ
Intellia Therapeutics Inc
$9.70
arrow_downward
-8.06%(-0.85) 1D
$9.80
arrow_upward
+1.03% (+0.10)bedtimeAfter hours
Closed: Nov 13, 4:00:00 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NTLA...
Open
$10.45
High
$10.50
Low
$9.66
Mkt. cap
1.36B
Avg. vol.
5.05M
Volume
11.42M
52-wk high
$18.48
52-wk low
$7.95
EPS
-$3.35
Beta
1.83
Shares outstanding
140.36M
No. of employees
377
Open
$10.45
High
$10.50
Low
$9.66
Mkt. cap
1.36B
Avg. vol.
5.05M
Volume
11.42M
52-wk high
$18.48
52-wk low
$7.95
EPS
-$3.35
Beta
1.83
Shares outstanding
140.36M
No. of employees
377
News stories
From web sources and news partners
Investing.com Canada
·
8 hours ago
Form 8K Intellia Therapeutics Inc For: 13 November By Investing.com
Investing.com
·
20 hours ago
Intellia stock price target maintained at $30 by Citizens on HAE data
GuruFocus
·
1 day ago
Intellia Therapeutics (NTLA) Shares React to Positive HAE Treatment Data at ACAAI 2026
Investing.com
·
1 day ago
Intellia presents lonvo-z data at allergy conference
Profile
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.
The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, and Virginijus Šikšnys. The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics.
Intellia has two in vivo programs in ongoing clinical trials.
The first, NTLA-2001, is being tested in two Phase 3 trials: MAGNITUDE, in ATTR cardiomyopathy, and MAGNITUDE-2, in hereditary ATTR polyneuropathy. Wikipedia
About Intellia Therapeutics Inc
CEOJohn Leonard
Employees377
Founded2014
HeadquartersCambridge, Massachusetts, United States
SectorHealth Care
IndustryBiotechnology
Websiteintelliatx.com